Skip to content
preclinicalMuscle & Performance

PEG-MGF

Also known as: Pegylated Mechano Growth Factor, PEGylated MGF, PEG-IGF-1Ec, Pegylated IGF-1 Splice Variant

PEG-MGF is a pegylated form of Mechano Growth Factor (MGF), itself a splice variant of IGF-1 (specifically the Ec isoform in humans). Standard MGF has an extremely short half-life of only minutes due to rapid enzymatic degradation, severely limiting its practical utility. By attaching a polyethylene glycol (PEG) polymer to the peptide, PEG-MGF achieves a dramatically extended half-life of several days, allowing systemic administration rather than requiring localized injection. MGF is naturally expressed in mechanically loaded muscle tissue and plays a key role in activating satellite cells for muscle repair and hypertrophy.

3 cited references·5 researched benefits

Quick Answer

PEG-MGF is a pegylated version of Mechano Growth Factor, a splice variant of IGF-1 that is naturally produced in mechanically stressed muscle tissue. Pegylation extends the half-life from minutes to several days, enabling systemic administration. PEG-MGF activates muscle satellite (stem) cells, promotes myoblast proliferation, and supports muscle repair and hypertrophy. It remains a preclinical research compound studied for muscle wasting, injury recovery, and age-related muscle loss.

Key Facts

Mechanism
MGF (the Ec splice variant of IGF-1) is produced locally in muscle tissue following mechanical loading or damage. It acts primarily on muscle satellite cells — adult muscle stem cells — activating them from quiescence and promoting their proliferation and differentiation into new muscle fibers. MGF signals through a distinct mechanism from mature IGF-1: while mature IGF-1 promotes differentiation via the IGF-1R receptor, MGF preferentially activates satellite cell proliferation through unique C-terminal domain interactions that are not fully characterized. The PEG modification protects the peptide from rapid proteolytic degradation, increasing its half-life from approximately 5–7 minutes to several days and allowing it to circulate systemically rather than acting only locally.
Research Status
preclinical
Half-Life
~several days (vs ~5–7 minutes for non-pegylated MGF)
Molecular Formula
C₁₂₁H₂₀₀N₄₂O₃₉ (MGF peptide core, PEG moiety varies)
Primary Use
Muscle & Performance
Table of Contents

Benefits

  • Activates muscle satellite (stem) cells, promoting muscle repair and regenerationmoderate
  • Extended half-life allows systemic administration rather than localized injection required by standard MGFmoderate
  • Promotes myoblast proliferation — supports hypertrophy in muscle recovery from exercise or injurymoderate
  • Potential application for age-related sarcopenia (muscle wasting) by restoring satellite cell activationpreliminary
  • May accelerate recovery from musculoskeletal injuries including muscle tears and strainspreliminary

Dosage Protocols

RouteDosage RangeFrequencyNotes
Subcutaneous injection200–500 mcg2–3× per weekExtended half-life from pegylation allows less frequent dosing than standard MGF. Often dosed on training days. No standardized human dosing protocols exist.
Intramuscular injection (site-specific)200 mcg per site2–3× per weekSome protocols advocate bilateral injection into the target muscle group post-training. Systemic effects also occur due to extended circulating half-life from PEG moiety.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Injection site reactions — pain, redness, or swelling, potentially more pronounced due to PEG moietycommon
  • Potential localized hypoglycemia at injection site due to IGF-1 pathway activationrare
  • Theoretical risk of uncontrolled cell proliferation with chronic supraphysiologic dosingserious
  • Immune reaction to PEG moiety in rare individuals with anti-PEG antibodiesrare
  • Limited human safety data — most evidence comes from animal modelsrare

Frequently Asked Questions

What is the difference between MGF and PEG-MGF?
Standard MGF (Mechano Growth Factor) is an unmodified 24-amino-acid peptide corresponding to the unique C-terminal extension of the IGF-1Ec splice variant. It has a half-life of only about 5–7 minutes, requiring frequent localized injections directly into the target muscle to have any meaningful effect. PEG-MGF has a polyethylene glycol (PEG) polymer attached, which shields it from enzymatic degradation and extends the half-life to several days. This allows less frequent dosing and systemic circulation, making it far more practical for research and potential therapeutic application.
Is PEG-MGF the same as IGF-1?
Not exactly. MGF is a splice variant of the IGF-1 gene — specifically the Ec isoform. When the IGF-1 gene is transcribed in mechanically loaded muscle, it can be spliced differently to produce either mature IGF-1 or MGF. While both originate from the same gene, they have different C-terminal sequences and distinct biological roles. Mature IGF-1 primarily promotes differentiation of existing muscle cells, while MGF preferentially activates satellite cell proliferation — the recruitment of new muscle stem cells. PEG-MGF is the pegylated version of this splice variant.
Can PEG-MGF be stacked with other growth peptides?
In research contexts, PEG-MGF is sometimes combined with IGF-1 LR3 in a sequential protocol: PEG-MGF is used first to activate and proliferate satellite cells (expanding the pool of muscle precursor cells), followed by IGF-1 LR3 to promote differentiation and maturation of those cells into functional muscle fibers. Some protocols also combine it with GH secretagogues (GHRP/GHRH) or recovery peptides like BPC-157 and TB-500. No standardized stacking protocols exist, and all such combinations remain experimental.
Is PEG-MGF approved for human use?
No. PEG-MGF is a preclinical research compound that has not completed human clinical trials or received regulatory approval in any country. It is classified as a research chemical and is prohibited by the World Anti-Doping Agency (WADA) under the category of peptide hormones and growth factors. Any use is considered experimental and is at the individual's own risk.

References

  1. 1
    Mechano growth factor: a splice variant of IGF-I that activates muscle satellite cells(2004)PubMed ↗
  2. 2
    Local expression of IGF-1 splice variants and their role in muscle hypertrophy and repair(2005)PubMed ↗
  3. 3
    Mechano growth factor, its variants, and implications for muscle repair and aging(2007)PubMed ↗

Latest Research

Last updated: 2026-02-19